H A L F -Y EA R R E P O RT 2 0 1 5

Key figures of HAEMATO AG

Key Group performance indicators (IFRS) in kEUR

Group profit and loss summary account 01.01. - 30.06.2015

Sales 101,477

EBIT 4,211

Net profit 2,768

Group balance sheet 30.06.2015

Short-term assets 52,712

Long-term assets 51,946

Equity 55,517

Liabilities 49,141

Balance sheet sum 104,658

Equity ratio 53.0 %

Key data of the HAEMATO share 30.06.2015

Number of shares in circulation 20,778,898

WKN 619070

ISIN DE0006190705

Stock symbol HAE

Level of transparency Entry Standard

Stock market segment Open Market

1

f Letter to the shareholders 2 f Group interim management report 3

1. Company profile 4

2. Economic environment 5

Global economy 5Economic situation in Germany 6The German pharmaceuticals market 7

3. Economic situation 8

Financial status and results 8

4. Outlook 9

f Group interim financial statements 11

Group balance sheet - Assets 12Group balance sheet - Liabilities 13Group profit and loss summary account 14Group cash flow statement 15Group equity change account 16Group assets development 17

f Condensed notes 18 f Further information 21

Information about the members of the company bodies 22The share 23The participation certificate 23Glossary 24Sources 25Imprint 26

Content

2

In the second quarter of 2015 HAEMATO generated sales of 56.32 million Euro.

Sales of the first quarter amounting to 45.16 million Euro were ex-ceeded. The tightenings in the pharmaceutical supervision, which led to a considerable reduction of the stock turn rate were lifted in May 2015. At 1.55 million Euro, the period’s net profit of the sec-ond quarter 2015 surpassed the result of the first quarter totalled 1.23 million Euro.

Especially in the months of May and June, the first half of the year 2015 showed growth during the period with sales of 101.48 million Euro and a net profit of the period of 2.77 million Euro. On this basis we are confident to achieve further growth for the second half of the year.

For the whole 2015, we are aiming at a profit realization of more than 30 Cents per share. The dividend for the year 2015 shall amount to at least 30 Cents per share as well.

Dr. Christian PahlManagement Board

August 2015

Dear shareholders,Ladies and Gentlemen

3

Group interim management report

f 1. Company profile 4 f 2. Economic environment 5

Global economy 5Economic situation in Germany 6The German pharmaceuticals market 7

f 3. Economic situation 8

Financial status and results 8

f 4. Outlook 9

4

Group interim management report

Group interim management report • Company profile

1. Company profile

HAEMATO AG is a listed pharmaceutical compa-ny. The focus of the business activities lies on the growth markets of patent free and patent protect-ed medicinal products.

Focal points are therapies for cancer, HIV, neuro-logical, cardiovascular and other chronic diseases. Another field is the high-margin market of private patients. In this area HAEMATO AG focuses on the fast growing market of aesthetical medicine with its offer of hyaluronic acid and botulinum toxin.

As a result of the rising life expectations within the population, the demand for inexpensive medicines, supplied in top quality and meeting the demands for a reliable and comprehensive medical care, will continue to rise in the coming years. With our product portfolio of patent free and patent protect-ed medicines we support the optimisation of an ef-ficient supply of medicinal products and thereof the reduction of costs for health insurance providers and finally also for patients.

5Group interim management report • Economic environment • Global economy

After the world economy expanded more dynami-cally last autumn, the economic development de-clined markedly in spring 2015. The expansion rate of the industrial production slowed considerably in the developed nations as well as in the emerg-ing economies. World trade followed a downward trend, too, after a strong growth in the second half of the last year.1

The slight expansion in the first three months of this year was mainly due to the decrease of the aggregated production in the USA. Primarily re-sponsible were special factors that in the meantime have no longer any impact. The very cold winter and strikes on the most important ports on the west coast burdened the export. Additionally the strengthening of the US dollar since summer 2014 adversely affected the export industry and led to a negative contribution of foreign trade of 0.5 %. However, the underlying pace of the U.S. remains positive. The good development of the labour mar-ket, the associated improved financial situation of the private households as well as the low oil price sustain the domestic economy strongly.2

2. Economic environment

Global economy

The subdued economic activity in the USA had a negative impact on most threshold countries. There the expansion of the industrial production also slowed considerably.3

In contrast, the output growth in the euro area and in Japan could accelerate, due to the favourable development of the raw material prices and a sharp devaluation of the currencies.4 All in all the recov-ery in the euro area slightly gained momentum. In the first quarter 2015 as well as in the fourth quar-ter 2014 real gross domestic product increased by 0.4 %. In the previous two quarters growth rates only amounted to 0.2 % resp. 0.1 %. Besides the devaluation of the Euro and the low crude oil pric-es the moderate upswing is additionally supported by government and private consumption. Never-theless, the persistently high level of uncertainty regarding the development of Greece as well as the unresolved structural problems in France and Italy remains.5

6 Group interim management report • Economic environment • Economic situation in Germany

Following a moderate start to the year, German economy regained some of its momentum. Thus, the gross domestic product grew by 0.3 % in the first quarter of this year. Due to the favourable pro-duction figures, experts of the Institute for World Economy assume in their latest forecast an in-crease by 0.5 % in the second quarter 2015.6

Particularly, industry could expand its production. So sales could be increased significantly in the past two months and reached the highest level since seven years.7 Especially positive impulses from abroad have boosted this trend. The ongoing re-covery in the euro area as well as the low euro exchange rate led to an above-average rise in or-ders from abroad.8 Based on the strong domestic economy imports will experience a very dynamic growth. However, the devaluation of the euro will have a dampening effect.9

Economic situation in Germany

Under the positive influence of the continuing fa-vourable development of the labour market, the private consumption still remain the growth driv-er of the German economy. In June 2015 the un-employment rate dropped to 6.2 %. With a sea-sonally adjusted unemployment rate of 4.7 % in May, calculated in accordance to the standards of the International Labour Organization (ILO), Ger-many actually notes one of the lowest unemploy-ment rates in the industrial nations. Furthermore, the disposable incomes in Germany increase no-ticeable, due to an only moderate price increase. Though the price level has developed more dynam-ically in the second quarter again, the general price climate remains favourable as a result of the low energy costs.10

Change in the gross domestic product (GDP) in Germany compared to the previous quarter (adjusted by price, seasonal and calendar effects)

1.9 %

0.2 % 0.4 %

0.0 %

0.4 %

0.1 % 0.2 %

- 0.5 % - 0.3 %

0.9 %

0.4 % 0.3 %

0.7 %

-0.1 %

0.2 %

0.6 %

0.3 % 0.5 %

-1.0 %

-0.5 %

0.0 %

0.5 %

1.0 %

1.5 %

2.0 %

Q2'11 Q4'11 Q2'12 Q4'12 Q2'13 Q4'13 Q2'14 Q4'14 Q2'15

Source: Federal Statistical Office; Institute for World Economy

7Group interim management report • Economic environment • The German pharmaceuticals market

Over the last 60 years healthcare in Europe has im-proved significantly. Subsequently, life expectancy of Europeans increased by nearly a decade since the 1950s. This progress is particularly due to the pharmaceutical industry.11 As a consequence of the increased life expectancy and the technological progress, the pharmaceuticals market is one of the growth segments, especially in Germany.

In the first half of 2015 the whole pharmaceuticals market in Germany experienced growth by sales of about 6.3 % to 18.7 billion Euro. Unit sales in-creased by 3.1 %. In the first six months of 2015, the pharmacy market, that dominates the phar-maceuticals market, rose by 7.3 % to 15.5 billion Euro. Prescription drugs, which constitute 85.1 % of the pharmacy market, recorded an increase by sales of 7.0 %. Sales quantity of prescription med-icine rose by 1.7 %.12

In the pharmacy market, generics recorded a sales increase of 6.0 %. Original medicines even grew by 18.7 %. Especially new product launches for the therapy of hepatitis C were responsible for this strong augmentation. Thereby the drug group of virustatics exclusive HIV products accounted for 46 % of the whole sales increase in the pharmacy market. The group of oncological therapies contrib-uted 6 % to the sales growth.13

The German pharmaceuticals market

In the statutory health insurance market the com-pulsory manufacturer discount amounted to 1,155 million Euro for the period from January to June 2015. Thus savings are 16 % above the previ-ous year’s figure. The compulsory manufacturer discount for the private health insurance grew by 17 % in comparison to the prior year’s period. This growth was mainly due to an increased compul-sory manufacturer discount for patent protected medicines not subject to the reference pricing from 6 % to 7 % in the second quarter. All in all, the savings volume in the first half of 2015 realised by the manufacturer in favour of the statutory health insurance amounted to 1.2 billion Euro. Due to the strong wave of influenza, pharmaceutical expenditure of the statutory health insurance still increased by 7.5 % in the first quarter of 2015, taking into account rebate contracts and manufac-turer discounts.14

The association of the research-based pharma-ceutical companies in Germany considers the fur-ther development of the German pharmaceuticals market optimistically. For the whole year 2015 the association presumes a sales growth of about 3 %. Particularly the strong innovative component should fuel the sales increase.15

2,364

13,161

15,525

3,262

9,752

2,511

Over the counterPrescription medicine

Total real ex-manufacturer prices

GenericsOlder original + patent protected preparations (incl.

second supplier) Rest*

Sales composition of the German pharmacy market in the first half of 2015ex-manufacturer prices less compulsory manufacturers discounts in million Euro

*Vaccines, test diagnostics, therapeutics to substi-tute endogenous substances

Source: IMS Health market reports

8 Group interim management report • Economic situation • Financial status and results

3. Economic situation

Financial status and results

a. Assets situation of HAEMATO Group (IFRS)

The financial position of the HAEMATO Group is good. The financial position of the HAEMATO Group is characterised by an increase in stocks of 2,165 kEUR to 36,353 kEUR as of June 30, 2015 and a decrease in trade receivables of 606 kEUR to 9,872 kEUR as of June 30, 2015. Particularly due to the payment of a dividend to the amount of 6,234 kEUR, liquid assets declined by 384 kEUR to 2,040 kEUR as of 30.06.2015.

b. Financial situation of HAEMATO Group (IFRS)

Our financial position can be designated as being very stable. Our financial management is directed to the settlement of liabilities within the payment deadline and to the collection of receivables within the terms of payment.

Our capital structure is good. After payment of a dividend to the amount of 6,233,669.40 Euro and the generation of half-year profit of 2,767,610.37 Euro, equity declined by 3,466,059.03 Euro from 58,983 kEUR (31.12.2014) to 55,517 kEUR (30.06.2014). Equity ratio decreased from 58.0 % (31.12.2014) to 53.0 % (30.06.2015). c. Earnings situation of HAEMATO Group

(IFRS)

In the first half of 2015 business development was characterised by impacts of temporary (July 2014 to April 2015) tightenings in the pharmaceutical regulations, which led to a reduction of the stock turn rate. With 101.48 million Euro, sales were below the previous year’s figure of 114.13 million Euro. Material cost as a percentage of sales of the corporate group was 92.4 % compared to 90.0 % in the first half of 2014.

Our financial position can overall be termed as be-ing good

9

4. Outlook

Economic output in the USA shall grow stronger than in the Euro area or Japan. In the Euro area numerous structural problems still weaken the economic development. Due to structural reforms, that were implemented in several member states, the respective negative impacts are decreasing gradually. For 2015 the Leibniz Institute for Eco-nomic Research expects the gross domestic prod-uct to grow by 3.2 %. In the course of the year 2016 the institute assumes a slight decline of the economic dynamism. As in the first quarter of this year economic output was low, in 2016 the world economy will grow more strongly than in 2015 at a rate of 3.7 %.16

As the general conditions for the German econ-omy remain favourable, the Leibniz Institute for Economic Research is assuming a continuation of the upturn. The private consumption will remain the main driver of the growth. The current pace of the private consumption, however, will not be maintained. In the second half of 2015, exports

will still be boosted by the devaluation of the Euro. As a consequence of the strong domestic economy, imports will grow somewhat faster than the ex-ports. All in all, the Leibniz Institute for Economic Research expects an increase of the gross domes-tic product of 1.9 % in this year and a rise of 1.8 % in the next year.17

Due to the austerity measures, implemented by the governments as a result of the economic crisis, the European pharmaceuticals market will grow only by about one to four per cent annually until 2018. The greatest growth within the EU 5 nations is expected in Great Britain and Germany.18 Thus, as one of the fast-growing markets in Europe, Germany will still be ranked on the fourth place worldwide.19 According to the IMS Health Institute, patent-protected specialty medicines and generics will still constitute the driver.20 With its focus on generics and cost-effective specialty medicines the HAEMATO Group considers itself well positioned for the future.

Group interim management report • Outlook

0 100 200 300 400 500

USA

China

Japan

Germany

Brazil

France

Great Britain

Forecast min. Forecast max.

Prognosted pharmaceutical expenditure of leading countries in 2018in bn. Euro

Source: IMS Health.

10

11

Group interim financial statements

Group balance sheet - Assets 12

Group balance sheet - Liabilities 13

Group profit and loss summary account 14

Group cash flow statement 15

Group equity change account 16

Group assets development 17

12 Group interim financial statements • Group balance sheet - Assets

Group balance sheet - AssetsAccounting under IFRS

30.06.2015EUR

31.12.2014kEUR

Cash 2,039,781.03 2,424

Trade receivables 9,872,276.63 10,478

Inventory 36,352,641.58 34,188

Other financial short-term assets 2,715,212.77 2,743

Other short-term assets 397,514.32 174

Income tax receivables 1,334,165.64 1,553

Short-term assets 52,711,591.97 51,559

Intangible assets 6,227,135.69 6,770

Company value 34,583,688.64 34,584

Tangible assets 1,181,172.66 1,094

Prepayments 75,600.00 84

Financial assets 9,750,185.08 7,480

Other long-term assets 128,677.20 130

Long-term assets 51,946,459.27 50,142

f TOTAL ASSETS 104,658,051.24 101,701

13Group interim financial statements • Group balance sheet - Liabilities

Group balance sheet - LiabilitiesAccounting under IFRS

30.06.2015EUR

31.12.2014kEUR

Accruals 3,093,120.93 3,243

Bank loans 12,241,278.12 12,553

Trade payables 11,290,306.44 7,244

Other financial short-term liabilities 3,300,108.71 474

Other short-term liabilities 2,002,639.12 2,148

Short-term liabilities 31,927,453.32 25,663

Accruals 20,935.41 21

Bond loan (Participation certificate) 5,209,300.00 5,209

Bank loans 11,000,000.00 10,750

Deferred tax 983,752.84 1,076

Long-term liabilities 17,213,988.25 17,056

Share capital 20,778,898.00 20,779

Capital reserve 7,571,981.01 7,572

Legal reserve 1,155,154.89 1,155

Other revenue reserve 4,136,318.79 4,136

Balance sheet profit 21,874,256.98 25,340

Equity 55,516,609.67 58,983

fTOTAL LIABILITIES 104,658,051.24 101,701

14 Group interim financial statements • Group profit and loss summary account

Group profit and loss summary accountAccounting under IFRS

01.01.-30.06.2015

EUR

01.01.-31.12.2014

kEUR

Sales 101,477,042.09 202,674

Other operating income 2,979,797.99 4,501

Cost of materials

Cost of purchased goods and services -93,738,260.51 -186,375

Labour costs

Salaries -2,049,890.26 -3,732

Social insurance contribution -423,959.13 -770

-2,473,849.39 -4,502

Depreciation / Amortisation -887,272.85 -2,056

Other operational expenses -3,146,922.49 -6,009

EBIT (earnings before interest and tax) 4,210,534.84 8,233

Interest income 5,779.57 185

Financial investment depreciations -311,193.60 0

Interest expenses -784,703.89 -1,551

Financial result -1,090,117.92 -1,366

EBT (earnings before tax) 3,120,416.92 6,867

Income tax -350,748.70 112

Other tax -2,057.85 -1

Net profit for the reporting period 2,767,610.37 6,978

15Group interim financial statements • Group cash flow statement

Group cash flow statementAccounting under IFRS

01.01. - 30.06.2015

EUR

01.01. - 31.12.2014

kEUR

Operating activities

1. Earnings before taxes on income and profit minus other taxes 3,118,359.07 6,866

2. Depreciation / Amortisation 887,272.85 2,056

3. Change in long-term accruals 0.00 -58

4. Change in financial asset valuation -1,625,363.40 -3,1855. Profit / loss from the disposal of fixed assets and from the sale of

shares in subsidiaries -850,265.70 -4,447

6. Interest and investment income -5,779.57 -185

7. Interest expense 784,703.89 1,551

8. Change in trade receivables and other assets -5,825,336.52 6,645

9. Change in inventory -2,165,008.79 -3,402

10. Change in trade payables, other liabilities and sort-term accruals 6,948,178.88 2,989

11. Cash Flow from company activities 1,266,760.71 8,831

12. Interest income and dividends received 5,779.57 183

13. Interest expense paid -986,869.24 -1,551

14. Income tax paid -611,801.33 -902

-1,592,891.00 -2,270

15. Cash Flow from operating activities -326,130.29 6,561

Investment activities

1. Payments for the acquisition of fixed assets and acquisition ofsubsidiaries -6,938,170.94 -5,645

2. Proceeds from the disposal of fixed assets and the disposal ofsubsidiaries 13,176,238.76 3,813

3. Cash Flow from investment activities 6,238,067.82 -1,833

Financing activities

1. Sale of own shares 0.00 430

2. Dividend paid -6,233,669.40 -6,234

3. Change in bank loans -62,200.13 183

4. Cash Flow from investment activities -6,295,869.53 -5,621

Cash Flow -383,932.00 -892

Cash and cash equivalents

1. 30 June 2015 / 31 December 2014 2,039,781.03 2,424

2. 31 December 2014 / 31 December 2013 2,423,713.03 3,316

-383,932.00 -892

16

Gro

up

eq

uit

y ch

ang

e ac

cou

nt

as o

f Ju

ne 3

0, 2

015*

Sha

re c

apita

l EU

RLe

gal r

eser

ve

EUR

Cap

ital r

eser

ve

EUR

Bal

ance

she

et

profi

t EU

R

Oth

er r

even

ue

rese

rve

EU

RSub

-tot

al

EUR

Equi

ty o

f sh

areh

olde

rs o

f H

AEM

ATO

EU

RTo

tal e

quity

EUR

1. A

s of

31

Dec

embe

r 20

1320

,778

,898

.00

1,15

5,15

4.89

7,57

1,98

1.01

24,5

95,5

34.0

94,

136,

318.

7958

,237

,886

.78

58,2

37,8

86.7

858

,237

,886

.78

2. P

erio

d in

com

e0.

000.

000.

006,

978,

451.

320.

006,

978,

451.

326,

978,

451.

326,

978,

451.

32

3. D

ivid

ends

0.00

0.00

0.00

-6,2

33,6

69.4

00.

00-6

,233

,669

.40

-6,2

33,6

69.4

0-6

,233

,669

.40

4. A

s of

31

Dec

embe

r 20

1420

,778

,898

.00

1,15

5,15

4.89

7,57

1,98

1.01

25,3

40,3

16.0

14,

136,

318.

7958

,982

,668

.70

58,9

82,6

68.7

058

,982

,668

.70

5. P

erio

d in

com

e0.

000.

000.

002,

767,

610.

370.

002,

767,

610.

372,

767,

610.

372,

767,

610.

37

6. D

ivid

end

0.00

0.00

0.00

-6,2

33,6

69.4

00.

00-6

,233

,669

.40

-6,2

33,6

69.4

0-6

,233

,669

.40

7. A

s of

30

June

201

520

,778

,898

.00

1,15

5,15

4.89

7,57

1,98

1.01

21,8

74,2

56.9

84,

136,

318.

7955

,516

,609

.67

55,5

16,6

09.6

755

,516

,609

.67

* Acc

ount

ing

unde

r IF

RS

Group interim financial statements • Group equity change account

17

Acq

uisi

tion

cost

Cum

ulat

ive

depr

ecia

tion

/ am

ortis

atio

n

Boo

k va

lue

As

of

01.0

1.20

15EU

RAdd

ition

/Rec

l.EU

RD

ispo

sal/

Recl

. EU

R

As

of 3

0.06

.201

5EU

R

As

of

01.0

1.20

15EU

RAdd

ition

EU

RD

ispo

sal

EU

R

As

of 3

0.06

.201

5EU

R

As

of

30.0

6.20

15EU

R

As

of

31.1

2.20

14

EUR

I. I

ntan

gibl

e as

sets

1. I

ntan

gibl

e as

sets

14,4

09,0

61.6

624

5,10

6.51

-2,5

00.0

014

,651

,668

.17

7,63

8,75

1.65

787,

384.

83-1

,604

.00

8,42

4,53

2.48

6,22

7,13

5.69

6,77

0,31

0.01

2. C

ompa

ny v

alue

34,5

83,6

88.6

40.

000.

0034

,583

,688

.64

0.00

0.00

0.00

0.00

34,5

83,6

88.6

434

,583

,688

.64

48,9

92,7

50.3

024

5,10

6.51

-2,5

00.0

049

,235

,356

.81

7,63

8,75

1.65

787,

384.

83-1

,604

.00

8,42

4,53

2.48

40,8

10,8

24.3

341

,353

,998

.65

II. F

ixed

ass

ets

1,57

4,86

0.11

239,

827.

20-5

2,30

0.52

1,76

2,38

6.79

481,

326.

1199

,888

.02

0.00

581,

214.

131,

181,

172.

661,

093,

534.

00

III.

Pre

paym

ents

84,3

56.2

565

,817

.17

-74,

573.

4275

,600

.00

0.00

0.00

0.00

0.00

75,6

00.0

084

,356

.25

IV. F

inan

cial

ass

ets

4,38

8,43

8.45

6,51

5,19

0.00

-3,2

47,0

04.6

77,

656,

623.

78-3

,091

,978

.79

-1,6

25,3

63.4

02,

623,

780.

89-2

,093

,561

.301

)9,

750,

185.

087,

480,

417.

24

TOTA

L55

,040

,405

.11

7,06

5,94

0.88

-3,3

76,3

78.6

158

,729

,967

.38

5,02

8,09

8.97

-738

,090

.55

2,62

2,17

6.89

6,91

2,18

5.31

51,8

17,7

82.0

750

,012

,306

.14

Gro

up

ass

ets

dev

elop

men

tas

of

30 J

une

2015

*

* Acc

ount

ing

unde

r IF

RS

1) A

ppre

ciat

ion

of e

xist

ing

finan

cial

ass

ets.

A m

inus

sig

n sh

ows

the

appr

ecia

tion

abov

e ac

quis

ition

cos

ts.

Group interim financial statements • Group assets development

18

1. General information

Condensed notesas of 30.06.2015 (unaudited)

The HAEMATO AG was established on May 10, 1993. The company is registered in the commer-cial register of the local court Berlin-Charlotten-burg under HRB 88633 and has its domicile in Ber-lin. Its business address is Lilienthalstr. 5 c, 12529 Schönefeld. The MPH Mittelständische Pharma Holding AG is the parent company of HAEMATO AG.

The HAEMATO Group operates in the pharmaceu-tical area.

The condensed consolidated interim financial state-ments for the period from January 1 to June 30, 2015 of HAEMATO AG was voluntarily prepared in accordance with the International Financial Report-ing Standards (IFRS) of the International Account-ing Standards Board (IASB) and interpretations of the International Financial Reporting Interpreta-tions Committee (IFRIC) taking into consideration IAS 34 “Interim Reporting” as they are to be ap-plied in the European Union. The figures are un-audited.

The values for the current reporting period and for the previous year are stated in kEUR.

Concerning the accounting, valuation and consoli-dation methods as well as the exercise of options included in the IFRS we refer to the consolidated notes of the consolidated financial statements as of December 31, 2014.

2. Basis of consolidation

The basis of consolidation remained unchanged during the reporting period. Please refer to the information provided in the consolidated financial statements as of December 31, 2014.

3. Selected information on the con-solidated balance sheet and on the consolidated profit and loss summary account

The liquid assets, amounting to a total of kEUR 2,040 (31.12.2014: kEUR 2,424), comprise mainly bank deposits and are recorded with their nominal values.

The trade receivables, amounting to a total of kEUR 9,872 (31.12.2014: kEUR 10,478), are rec-ognised at amortised cost using the effective inter-est rate method minus potential impairments.

Under the inventories, which amount to a total of kEUR 36,353 (31.12.2014: kEUR 34,188), fin-ished products are shown, which have been valued at acquisition or production costs. According to IAS 2, all costs which have occurred in relation to the acquisition of the respective inventories have been included.

There have not been any costs for debt to be rec-ognised in the balance sheet. IAS 11 is not to be applied.

The other operating expenses, totalling kEUR 3,147 (01.01.-31.12.2014: kEUR 6,009), are spread over multiple positions, like e.g. rent, ad-vertising and travelling expenses, legal and con-sulting fees etc.

Condensed notes • General information • Basis of consolidation • Selected information on the consolidated balance sheet and on the consolidated profit ...

19Condensed notes • Dividend • Contingent liabilities and other financial obligations • Events after the financial statement date 30.06.2015

4. Dividend

For the financial year 2014, a dividend of 0.30 Euro per dividend-bearing share was distributed in 2015.

5. Contingent liabilities and other financial obligations

Together with HAEMATO AG, HAEMATO PHARM GmbH is jointly and severally liable to Inves-titionsbank of Brandenburg to the amount of EUR 214,440.00 (enforceable guarantee), in order to cover liabilities from the subsidy relationship be-tween ILB and the Simgen GmbH that has merged with HAEMATO PHARM GmbH. Additionally, HAE-MATO PHARM GmbH is jointly and severally liable together with MPH Mittelständische Pharma Hold-ing AG to Investitionsbank of Brandenburg, in or-der to cover liabilities from the subsidy relationship between ILB and HAEMATO PHARM GmbH to the amount of EUR 1,478,400.00 (enforceable guaran-tee).

In connection with the master agreement for fi-nancial futures between HAEMATO PHARM GmbH and Landesbank Baden-Württemberg there exists a cumulative assumption of debt as joint debtor to-gether with MPH Mittelständischen Pharma Holding AG to Landesbank Baden-Württemberg.

Together with MPH Mittelständische Pharma Hold-ing AG, HAEMATO AG is liable to HYPO NOE Gruppe Bank AG as joint debtor in connection with a bond-ed loan of EUR 7 million. This loan was disbursed to MPH Mittelständische Pharma Holding AG.

Together with MPH Mittelständische Pharma Hold-ing AG, HAEMATO AG is liable to HYPO NOE Gruppe Bank AG as joint debtor in connection with another bonded loan of EUR 3 million. This loan was dis-bursed to MPH Mittelständische Pharma Holding AG.

The claims from the contingent liabilities are not expected to be asserted based on the current cred-itworthiness and the beneficiaries‘ previous pay-ment practices. There are no recognisable indica-tions that would require a different assessment.

The other financial obligations are all within the scope of ordinary business.

6. Events after the financial state-ment date 30.06.2015

As of July 30, 2015 HAEMATO AG together with MPH Mittelständische Pharma Holding AG signed a further bonded loan of EUR 4 million with deben-ture donors.

After the balance sheet date as of June 30, 2015 and before the date of publication further essential events have not occurred.

Schönefeld, August 28, 2015

Dr. Christian Pahl (Management Board)

20

21

Further information

Information about the members of the company bodies 22

The share 23

The participation certificate 23

Glossary 24

Sources 25

Imprint 26

22

Information about the members of the company bodies

Management board

Supervisory board

Further information • Information about the members of the company bodies

Surname First name Function Authority to act Profession

Dr. Pahl Christian Management Board Sole power of representation Graduate in business administration

Surname First name Function Profession

Grosse Andrea Chairwoman Lawyer

Prof. Dr. Dr. Meck Sabine Deputy Chairwoman University Professor and Science Journalist

Dr. Braun Marion Member Doctor

23

The share

Classes of shares Bearer sharesWKN / ISIN 619070 / DE0006190705Number of shares 20,778,898Stock symbol HAEListing Frankfurt Stock ExchangeStock market segment Entry Standard (Open Market)Designated Sponsor, Listing Partner ICF Kursmakler AGNominal capital 20,778,898.00 EURFirst day of trading 05.12.2005Specialist ODDO SEYDLER BANK AG

The participation certificate

Further information • The share • The participation certificate

WKN / ISIN A0EQVT / DE000A0EQVT2Stock symbol HAE1Type / Certification Bearer instruments, global certificateInitial listing 2005Basic value per certificate 100 EUR (minimum investment)Maturity Unlimited termAnnual distribution 9,00 % p.a. relating to nominal value of the par-

ticipation certificate (depending on balance sheet profit of HAEMATO AG)

Date of payment Subsequently on first bank working day following the General Meeting of HAEMATO AG

Market place Frankfurt Stock Exchange

24

Glossary

AMNOGGerman law for the restructuring of the pharma-ceutical market, which came into force on 1 Jan-uary 2011.

ApprovalAn official authorization which is required to be able to offer, distribute or provide an industrially produced, ready-to-use drug.

Balance sheet profitBalance of net profit of the financial year, profit or loss carried forward and appropriation of profits.

Cash FlowAn economic indicator informing on the liquidity of a company. It represents the increase of liquid funds during a period.

DAX DAX is the most important german share price in-dex. It reflects the development of the 30 largest companies in Germany with the highest turnover.

DividendThis is the part of distributed profit of a stock cor-poration attributed to an individual share.

Earnings per shareThe earnings per share result from dividing the group result by the weighted average of the num-ber of shares. The calculation is made according to IAS 33.

EBITIt means earnings before interest and taxes and is an indicator of the operating profit of a company in a given period.

EBITDA It means earnings before interest, taxes, deprecia-tion and amortization and corresponds to the EBIT plus depreciation and amortization of tangible and intangible assets.

GKVStatutory health insurance: forms part of the ger-man health system and is mandatory for all of the employees, whose annual remuneration is below the mandatory threshold for health insurance, and for many other person.

ILO (International Labour Organization)a specialised agency of the United Nations. Its re-sponsibility is to formulate and implement interna-tional labour and social standards.

OncologyOncology is the science dealing with cancer.

PatentIn application to drugs: for a newly developed pharmaceutical agent, an industrial property right is granted. In the EU, this market exclusivity limit-ed in time can last up to 20 years.

Patent-free drugsPatent-free agents are also called generic drugs. A generic drug is a drug that is a copy of another drug already on the market under a brand name with the same active agent. Generic drugs are therapeutic equivalents to the original preparation

Patent-protected drugs Branded drugs that on the one hand are marketed by the patent owner and on the other hand are purchased for a lower price within the EU member states as EU imported drugs on the basis of the legal base of the import.

Further information • Glossary

25

Sources

Further information • Sources

1 cf. ifo Institut. Leibniz-Institut für Wirtschaftsforschung: ifo Konjunkturprognose 2015. Deutsche Wirtschaft im Aufschwung. Preliminary version, Munich 17.06.2015, p. 3.

2 cf. ebd., p. 103 cf. ebd., p. 3.4 cf. id.5 cf. id., 19.6 cf. Institut für Weltwirtschaft: Kieler Konjunkturberichte Nr. 8 (2015/Q2). Deutsche Konjunk-

tur im Sommer 2015, p. 1f.7 cf. Bundesministerium für Wirtschaft und Energie: Schlaglichter der Wirtschaftspolitik. Mon-

atsbericht August 2015, p. 12.8 cf. id., p. 34.9 cf. Institut für Weltwirtschaft: Kieler Konjunkturberichte Nr. 8 (2015/Q2). Deutsche Konjunk-

tur im Sommer 2015, p. 4.10 cf. Bundesministerium für Wirtschaft und Energie: Schlaglichter der Wirtschaftspolitik. Mon-

atsbericht August 2015, p. 37-41.11 cf. European Federation of Pharmaceutical Industries and Associations (EFPIA): Annual Report

2014. Brussels, 02.06.2015, p. 16.12 cf. IMS Health: IMS Health Marktbericht. Entwicklung des deutschen Pharmamarktes im Juni

2015. August 2015, Frankfurt am Main, p. 12, 16.13 cf. id., p. 20, 25.14 cf. id., p. 27-31.15 cf. Pharmazeutische Zeitung online: Pharmamarkt 2014: Umsatzwachstum um 6 Prozent.

20.02.201516 cf. ifo Institut. Leibniz-Institut für Wirtschaftsforschung: ifo Konjunkturprognose 2015.

Deutsche Wirtschaft im Aufschwung. Preliminary version, Munich 17.06.2015, p. 7f.17 cf. id., p. 30.18 cf. IMS Health Inc.: IMS Health Market Prognosis, März 2014; IMS Institute for Healthcare

Informatics: Global Outlook for Medicines Through 2018, November 2014, S 13.19 see: IMS Health Inc.: IMS Institute for Healthcare Informatics: Global Outlook for Medicines

Through 2018, November 2014, p. 33.20 cf. IMS Health Inc.: IMS Institute for Healthcare Informatics: Global Outlook for Medicines

Through 2018, November 2014, p. 11.

26

Imprint

Lilienthalstraße 5c12529 Schönefeld

Phone: +49 (0) 30 897 30 86-70Fax: +49 (0) 30 897 30 86-79

E-Mail: info@haemato.deWeb: www.haemato.de

Investor Relations:ir@haemato.de

Supervisory board:Chairwoman of the supervisory board: Andrea GrosseDeputy chairwoman of the supervisory board: Prof. Dr. Dr. Sabine MeckMember of the supervisory board: Dr. med. Marion Braun

Management board: Dr. Christian Pahl

Registered office:Berlin, Register court Charlottenburg, HRB 88633 B

Conception, design and realisation:HAEMATO AG

Photos:© HAEMATO PHARM GmbH© diego cervo - fotolia.com

Further information • Imprint

HAEMATO AGLilienthalstraße 5c D-12529 Schönefeld

Tel.: +49 (0) 30 897 30 86-70 Fax: +49 (0) 30 897 30 86-79

info@haemato.de www.haemato.de